Taisho Deal Gives BioAge First Clinical Asset

HIF-PHI Targets Aging Disorders

Private US venture moves into the clinic with early-stage asset from Japanese partner with potential in aging disorders.

Slow-Down Sign_147945794_1200.jpg
BioAge Looks To Address Diseases Of Aging • Source: Shutterstock

A deal for exclusive global rights to a hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor developed by Japanese firm Taisho Pharmaceutical Co. Ltd. has given private US venture BioAge its first clinical-stage asset, which it intends to develop for multiple diseases of aging.

Characterizing the agreement as a “significant milestone”, Richmond, CA-based BioAge will make undisclosed upfront, development and commercial milestone payments based...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip